J&J, Viiv Healthcare deal

Johnson & Johnson’s Janssen Biotech Inc. unit partnered co-exclusively with ViiV to globally develop and commercialize a combination regimen of long-acting, injectable formulations of HIV infection therapies Edurant rilpivirine and cabotegravir. Edurant, a marketed small molecule diarylpyrimidine non-nucleoside reverse transcriptase inhibitor (NNRTI) from Janssen, and cabotegravir, a long-acting parenteral integrase strand transfer inhibitor (INSTI) from ViiV, met the primary endpoint in the ongoing Phase IIb LATTE 2 trial in HIV-1 infection. ViiV will lead Phase III development of the regimen and will be responsible for commercialization in the U.S., Canada, the U.K., France, Spain, Italy, Germany, Portugal, Belgium, the Netherlands, Switzerland, Australia and Japan. In other countries, both companies will commercialize it. The companies will manufacture and supply their individual drug formulations following approval. ...